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Objective: We sought o determine the role of partial eft ventriculectomy in 
patients with dilated cardiomyopathy. Methods: Since May 1996 we have 
performed partial left ventriculectomy in 53 patients, primarily (94%) in 
heart transplant candidates. The mean age of the patients was 53 years 
(range 17 to 72 years); 60% were in class IV and 40% in class III. 
Preoperatively, 51 patients were thought o have idiopathic dilated cardio- 
myopathy, one familial cardiomyopathy, and one valvular cardiomyopathy. 
As our experience accrued we increased the extent of left ventriculectomy 
and more complex mitral valve repairs. For two patients mitral valve 
replacement was performed. For 51 patients the anterior and posterior 
mitral valve leaflets were approximated (Alfieri repair); 47 patients also 
had ring posterior annuloplasty. In 27 patients (5!%) one or both papillary 
muscles were divided, additional left ventricular wall was resected, and the 
papillary muscle heads were reimplanted. Results: Echocardiography 
showed a significant decrease in left ventricular dimensions after resection 
(8.3 cm to 5.8 cm), reduction in mitral regurgitation (2.8+ to 0), and 
increase in forward ejection fraction (15.7% to 32.7%). Cardiac index did 
not increase significantly (2.2 to 2.4 L/min per square meter). Eight 
patients (15%) required a perioperative l ft ventricular assist device; one 
died and was the only perioperative mortality (1.9%). At 11 months. 
actuarial survival was 87% and freedom from relisting for transplantation 
was 72%. Conclusions: Improved selection criteria are necessary to avoid 
early failures, and much more follow-up and analyses of data are manda- 
tory. However, the operation may become a biologic bridge, or even 
alternative, to transplantation. (J Thorac Cardiovasc Surg 1997;114:755-65) 
T erminal heart disease is prevalent and expected to steadily increase. 1 Human heart transplanta- 
tion is severely limited by donor availability, which is 
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never expected to meet the overwhelming de- 
mand)  -3 The search for surgical alternatives to 
cardiac al!ografts includes mechanical devices, 4-6 
xenografts, 7 s eardiomyoplasty, 9'1° and high-risk 
"conventional" surgery. 11' la The increased opera- 
tive mortality of high-risk conventional surgery in 
patients with heart failure should be weighed against 
the mortality of transplantation: approximately 20% 
die while waiting for a donor heart, 20% die during 
the first year after transplantation, and mortality is 
5% per year thereafter) 3' 14 In addition, the cost of 
transplantation and the significant morbidity of im- 
munosuppression a d other medications have to be 
considered when deciding between high-risk con- 
ventional surgery and cardiac transplantation. 
An operation was developed by Batista and co- 
workerslS, 16 for patients with end-stage dilated car- 
755 
The Journal of Thoracic and 
7 5 6 McCarthy et al. Cardiovascular Surgery 
November 1997 
\ 
© 1997 
Fig. 1. Partial eft ventriculectomy (left) with the lateral wall and lateral branch of the circumflex coronary 
artery excised. After closure (fight) the LAD artery at the apex (point A) wraps around the reconstructed 
apex. The wall between the papillary muscles was resected, and during closure the papillary muscles were 
sutured together. 
diomyopathy of various etiologies. The concept of 
the operation is simple: returning the enlarged heart 
to a normal diameter will reduce left ventricular 
(LV) wall tension (the mechanism is related to the 
law of Laplace). To reduce the heart diameter, large 
segments of LV wall are resected (hence, Batista's 
terminology partial left ventriculectomy). The heart is 
then reconstructed to decrease the LV diameter. 
Clinical results from Brazil are difficult to interpret, 
but the perioperative mortality is approximately 
22% and the 2-year mortality approximately 45%. 
Most survivors are in improved clinical condition. 16 
We sought to study the operation prospectively; 
to determine whether it could be made safer with 
more sophisticated perioperative care and support, 
to assess the operation as a "biologic bridge" or even 
an alternative to transplantation, and to better clar- 
ify patient selection. This report details our early 
results and operative techniques and how they differ 
from those of Batista. 
Patients and methods 
Between May 1996 and April 1, 1997, 53 patients (mean 
age 53 years, range 17 to 72; 72% male) underwent partial 
left ventriculectomy, with mitral vane repair in 51 patients 
and mitral valve replacement in two patients. Our initial 
experience included primarily patients who were thought 
to have idiopathic dilated cardiomyopathy and who were 
candidates for heart transplantation. After further expe- 
rience we included three patients not eligible for trans- 
plantation and patients with other cardiomyopathy etiol- 
ogies (familia 1and valvular). 
Candidate selection was based on an LV end-diastolic 
diameter of 7 cm or more on at least one recent echocar- 
diographic study. Patients were not turned down for 
surgery on the basis of any reduced level of LV or right 
ventricular ejection fraction, pulmonary hypertension, mi- 
tral or tricuspid regurgitation, or incidental coronary 
artery disease. Among patients with the appropriate eft- 
ology and LV end-diastolic diameter, the most common 
reason ot to offer the operation was that the patient was 
"too well" and did not meet standard heart transplant 
listing criteriaJ 7All patients were reviewed and approved 
by the heart failure/transplant team, consisting of cardiol- 
ogists, surgeons, nurses, and social workers. All patients 
gave informed consent. Those eligible for transplantation 
were offered the option of waiting for that operation; 
those not eligible for transplantation were offered medical 
therapy. 
The 50 (94%) transplant candidates included 22 (44%) 
who had status I disease according to the criteria of the 
United Network for Organ Sharing (UNOS). Twenty-one 
(42%) were dependent on inotropic agents, two were also 
supported by an intraaortic balloon pumP (IABP), and 
one patient had been supported by the HeartMate im- 
plantable left ventricular assist device (LVAD) (Thermo 
Cardiosystems, Inc., Woburn, Mass.) for 88 days but had 
a devi'ce infection. The other 28 transplant candidates had 
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Fig. 2. To excise more LV wall, we transected one or both (left) papillary muscles and removed additional 
LV wall (dotted line). The resected heads of the papillary muscles were then resuspended with multiple, 
pledget-supported, full-thickness sutures (right). 
UNOS status II disease. Excluding the patient with the 
LVAD. 31 patients (60%) were in New York Heart 
Association (NYHA) functional class IV: the others were 
in class III. The patients in class III had had a mean of two 
admissions for congestive heart failure before the opera- 
tion. The condition of five of the 22 patients with status I
disease was steadily deteriorating (two requiring IABP 
support). These patients would alternatively have received 
implantable LVADs as a bridge to transplantation if 
partial left ventriculectomy had not been available. As 
further evidence of the end-stage condition of these 
patients, the mean (~ standard eviation) peak volume of 
oxygen use was 10 _~ 3.9 ml/kg per minute. 
Surgical and echocardiographic techniques. The oper- 
ation evolved from our earliest procedures using the 
methods of Batista (heart beating, single mitral valve 
repair stitch 16) to more complex valve repairs and car- 
dioplegic arrest during ventricular resection. Critical 
echocardiographic information obtained (both preopera- 
tive and intraoperative) included LV end-diastolic diam- 
eter and internal interpapillary muscle distance to guide 
the extent of resection. Intraoperative transesophageal 
echocardiography was performed in all patients. Standard 
esophageal nd transgastric views were obtained with the 
use of a HP Sonos 5.0/3.7 MHz probe with an HP Sonos 
1500/2500 echocardiography machine (Hewlett-Packard 
Co.. Palo Alto, Calif.). LV end-systolic and diastolic 
dimensions and volumes were calculated by the method of 
discs from the apical four-chamber view. The interpapil- 
lary distance, used to determine the expected size of the 
LV after the operation, was obtained from the short-axis 
view by measuring the distance between the insertion of 
the two papillary muscle heads into the endocardial 
surface. The severity of valvular egurgitation was deter- 
mined by standard color flow Doppler ultrasonography. 
Forward stroke volume, derived with the use of the 
velocity time integral from pulsed wave Doppler ultra- 
sonography of the LV outflow tract, is divided by the LV 
end-diastolic volume to obtain the forward ejection frac- 
tion After the operation, these variables were remea- 
sured, and the mitral valve gradient was calculated from 
the mitral inflow pressure half-time and confirmed by 
planimetry in the transgastric short axis. Wall motion 
information was collected but not used to guide the 
operation. 
The operation was performed with the use of cardio- 
pulmonary bypass with antegrade and retrograde cold 
blood cardioplegia for myocardial protection. The left 
atrium was opened in the interatrial groove and the 
Cosgrove-Edwards annuloplasty system (Baxter Health- 
care Corp., Edwards Div., Santa Ana, Calif.) was p!aced. 18 
A small ring undersizes the dilated anulus, and now we 
routinely use a No. 26 Cosgrove-Edwards ring (Baxter) to 
eliminate the central jet of mitral regurgitation. 
One patient unexpectedly had dense scar in the left 
anterior descending (LAD) and right coronary artery 
distributions. A limited anterior ventriculectomy was per- 
formed and she received an LVAD when she could not be 
weaned from cardiopulmonary b pass. Although she did 
not undergo typical partial left ventriculectomy, she is 
included in the series in the category "intention-to-treat 
failure." 
For the typical partial eft ventriculectomy resection the 
incision began approximately 2 cm lateral to the LAD 
artery and 3 cm proximal to the apex. The incision 
extended laterally along the base of the anterior papillary 
muscle of the mitral valve (Fig. 1). The apex of the 
incision was midway between the papillary muscles and 2 
cm from the mitral valve anulus. Typically this incision 
divided a large branch of the circumflex coronary artery, 
which was oversewn. At the apex, the incision then was 
extended 3cm parallel to the LAD artery and excised the 
LV apex (Fig. 1). The incision was then extended along 
the base of the posterior mitral valve papillary muscles 
and connected to the previous incision, thereby removing 
a large wedge of LV between the papillary muscles. 
The goal of ventriculectomy was to return the LV 
end-diastolic diameter to near-n0rmal. The LV end- 
diastolic diameter after resection was predicted by a 
simple formula: for every 3.14 cm (i.e., 7r) of LV muscle 
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Fig. 3. To decrease mitral regurgitation and avoid prolapse from redundant mitral valve chordae, we 
sewed the free edge of the anterior and posterior mitral valve leaflets (top left) together with a 4-0 suture 
(Alfleri repair). After this suture is tied, the mitral valve has a double orifice (bottom left). Echocardiog- 
raphy revealed low gradients across the mitral valve, a "figure-of-eight" appearance, and good mitral valve 
area (right). 
circumference resected, the LV end-diastolic diameter 
was decreased by 1 cm. Therefore, for a typical patient 
with an LV end-diastolic diameter of 8 cm and 6 cm of LV 
muscle between the papillary muscles, after partial left 
ventriculectomy between the papillary muscles, the new 
LV end-diastolic diameter would be 6 cm. If the LV 
end-diastolic diameter was very large and the distance 
between the papillary muscles mall, then we judged that 
we needed to remove more LV muscle and papillary 
muscle(s) to return the LV end-diastolic diameter to 
near-normal. In 27 patients (51%), on the basis of echo- 
cardiographic measurements and observation of the re- 
maining ventricle, we resected one or both papillary 
muscles. This allowed further esection of anterolateral or
posterior LV wall (Fig. 2). The remaining head of the 
resected papillary muscles (where the chordae arise from 
the muscle) were then resuspended with multiple full- 
thickness pledget-supported 3-0 polypropylene sutures 
(Fig. 2). 
Reconstruction of the ventricu!otomy approximated the 
papillary muscles or i"esuspended heads of the papillary 
muscles. Theoretically, this change in orientation of the 
papillary muscles may create redundant length to the 
chordae and, therefore, mitral regurgitation as a result of 
mitral valve prolapse. Batista avoids this problem by 
approximating the midportion of the free edge of the 
anterior and posterior leaflets (Alfieri repair) with a single 
suture.16. 19 The reconstructed mitral valve has a double 
orifice and looks like a figure-of-eight on postoperative 
echocardiograms (Fig. 3). Using a small annuloplasty ring 
also relieves tension on this suture. 
We closed the ventriculotomy in three layers, with strips 
of soft felt or bovine pericardium to help disperse tension 
over the long suture line. With the lateral wall removed 
and large portions of the remaining LV removed in 51% 
of patients with papillary muscle resuspension, there was 
considerable t nsion on the ventriculotomy closure. After 
closure, the distal LAD wrapped around the newly recon- 
structed LV apex (Fig. 1), the papillary muscle bodies 
were approximated toeach other, and the LV dimensions 
and volumes were decreased (Fig. 4). After both papillary 
muscles have been resected, the remaining LV consists of 
septum and a portion of the anterior and posterior walls 
(Fig. 4). 
Coronary arteries were bypassed in four patients with 
coronary artery lesions of more than 50%. The tricuspid 
valve was repaired if 2+ tricuspid regurgitation or greater 
was present. A De Vega tricuspid Valve repair was used in 
30 patients (57%) and a Cosgrove-Edwards ring was 
placed in one patient with 4+ tricuspid regurgitation. The 
right ventricle was never plicated as Batista has report- 
ed. ~6 One patient with moderate aortic insufficiency (2+) 
had aortic valve repair. One patient with combined mod- 
erate aortic stenosis and insufficiency (bicuspid valve) 
underwent aortic valve replacement. Mitral valve replace- 
ment was performed in two patients in whom mitral valve 
repair was not possible. One patient had rheumatic mitral 
valve disease and 2+ mitral regurgitation after initial 
attempted repair. The other had an unusual eccentric jet 
and had residual 2+ mitral regurgitation after attempted 
repair. Both underwent mitral valve replacement via left 
atriotomy. For patients who needed the implantable 
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Fig. 4. After resection and reconstruction, the LV diameter was reduced. In the most extreme cases, after 
resection of both papillary muscles, the remaining LV was composed primarily of septum and a portion of 
the anterior and posterior walls (left). Echocardiography demonstrates that the right ventricle (RV) wraps 
around most of the LV in these extreme cases (right). 
LVAD after partial left ventriculectomy, the technique for 
LVAD insertion was similar to that described in our 
previous report. 2° 
Statistical methods. Data have been presented as 
mean and standard eviation. Comparisons from one 
time point to another were done with the use of 
a paired t test. Survival and freedom from relisting 
for transplantation were calculated by means of the 
Kaplan-Meier method. 
Results 
The average weight of the resected specimen was 
96 gm (range 30 to 290 gin). Four of our earliest 
patients had only the Alfieri mitral valve repair (no 
mitral valve ring). These four patients had a reduc- 
tion in mitral regurgitation i itially, but at follow-up 
regurgitation had increased. Mean pressure gradi- 
ents across the mitral valve after the Alfieri repair 
were uniformly low (mean 2.85 _+ 1.43 mm Hg), and 
the mean mitral valve area (adding both orifices of 
the mitral valve) was 3.9 + 1.06 cm. Papillary 
muscles were resected and resuspended in 27 pa- 
tients (51%); both muscles were resected in nine 
patients (17%), the posterior papillary muscle only 
in 15 patients (28%), and the anterior papillary 
muscle only in three patients (6%). 
Thirty patients were weaned from eardiopulmo- 
nary bypass with the aid of inotropic drugs. Two 
patients had preoperative IABP support. IABPs 
were placed in four patients (8%) in an attempt to 
wean them from cardiopulmonary b pass. In all four 
patients, the IABP was inadequate. Two immedi- 
ately received an LVAD and two required a hepa- 
rin-coated extracorporeal membrane oxygenator; 
both required LVADs later. One patient received 
an IABP after chest closure because of rapid hemo- 
dynamic deterioration, which in retrospect was pre- 
cipitated by temporary right main stem intubation. 
This IABP was successfully removed the next morn- 
ing. 
Intraoperative transesophageal chocardiography 
showed a significant decrease in LV end-diastolic 
dimension, mitral regurgitation, and an increase in 
LV ejection fraction (Table I). The stroke volume 
did not significantly change. After the operation, 
typically the contractility of the anterior wall and 
septum improved. 
Before the operation, 21 patients required inotro- 
pic drugs, and inotropic agents were added in an- 
other nine patients because of hypotension and low 
cardiac output before the induction of anesthesia; 
therefore 30 patients (57%) were receiving inotropic 
agents before bypass. The cardiac index did not 
significantly increase after the operation, but the left 
atrial pressure, systemic blood pressure, and pulmo- 
nary artery pressures ignificantly decreased (Table 
II). Postoperative elevation of cardiac enzymes oc- 
curred in all patients, with a mean creatine kinase 
level of 1793 _+ 908 units the day of the operation 
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Table I. Echocardiographic changes in patients undergoing partial left ventriculectomy 
Preop: Intraop pre: Intraop post: After 1 weelc 
Variable Mean (SD) mean (SD) mean (SD) mean (SD) 
LVEDD (cm) 8.1 (1.0) 8.3 (1.1) 5.8 (0.7) 6.4 (0.6)? 
LVEDV (¢m) 319 (114) 251 (86) 117 (41)* 142.9 (40)t 
Forward LVEF (%) 13.7 (6.2) 15.7 (7.3) 32.7 (11)* 23.4 (7.9)t 
Mitral regurgitation (0-4+) 2.9 (1.0) 2.8 (1.1) 0.02 (0.1)* 0.2 (0.5)? 
Tricuspid regurgitation (0-4+) 1.6 (1.0) 1.3 (0.9) 0.14 (0.4)* 1.1 (1.0)t 
Stroke volume (ml) 41.2 (15):) 35.8 (17):) 36.1 (9.7):) 37.1 (10):) 
SD, Standard eviation; LVEDD, left ventricular end-diastolic dimension; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection 
fraction. 
*p < 0.001 intraop re to intraop ost. 
tp < 0.001 preop to 1 week. 
:~Changes in stroke volume, p not significant. 
and a total creatine kinase MB level of 220 _+ 72 
units (range 21 to 300 units). 
Eight patients (15%) required an LVAD in the 
perioperative period. Of these eight patients, one 
showed steady improvement in cardiac function and 
underwent successful LVAD removal after 86 days. 
Four successfully underwent transplantation a d are 
well. Two are alive and well as outpatients awaiting 
transplantation, and one died. The patient who died 
had a complicated course with LVAD insertion that 
also required insertion of a right ventricular assist 
device. Eventually, she died of Candida sepsis and 
multiple organ failure. This is the only perioperative 
mortality (1.9%). Two other patients could not be 
weaned from inotropic drugs and were relisted for 
cardiac transplantation. One of these patients ub- 
sequently underwent transplantation, and one was 
converted to an outpatient dobutamine regimen. 
Postoperative morbidity was common. Two pa- 
tients had transient renal failure necessitating dial- 
ysis; an additional two patients required dialysis 
after LVAD insertion. Two reoperations for bleed- 
ing were necessary (3.8%). Two patients required 
reintubation for respiratory failure and subsequently 
required tracheostomies. One patient had a major 
stroke in the distribution of a previous preoperative 
stroke, and one patient had a new transient ischemic 
attack. One patient had a saddle embolus to the 
aortic bifurcation on postoperative day 12, arising 
from new left atrial thrombus, In addition, of two 
patients who later underwent transplantation, one 
had mitral valve replacement with a mechanical 
valve and one patient had a left atrial thrombus 5 
months after the operation, despite routine postop- 
erative warfarin administration. 
For the patients not having an LVAD or trans- 
plantation, the mean hospital ength of stay was 13 
days (range 6 to 31 days). The average hospital 
charge for these patients was $54,165 _+ $28,624 
(range $30,395 to $187,317). Predischarge echocar- 
diography showed a significant persistent decrease 
in LV end-diastolic diameter, decrease in mitral 
regurgitation, and increase in LV ejection fraction 
(Table I). We believe the changes from the intraop- 
erative studies after partial left ventriculectomy are 
different from the 1 week studies because of differ- 
ent loading conditions. After surgery, medical ther- 
apy for heart failure was resumed for all patients 
and included angiotensin-converting e zyme inhib- 
itors, diuretics, and digoxin. Amiodarone was initi- 
ated because of sudden death in the Brazilian 
experience. Warfarin was instituted after the oper- 
ation because of the potential for LV thrombus 
along the suture line. 
Follow-up is complete in all patients and ranges 
from 1 to 11 months (mean 5 months). After 
discharge 16 patients were rehospitalized, and three 
were relisted for transplantation. One of these pa- 
tients eventually received an LVAD and died of 
multiple organ failure 87 days after partial left 
ventriculectomy and 20 days after LVAD insertion. 
Two patients died of presumed cardiac causes 100 
days and 209 days after partial eft ventriculectomy. 
One patient had a peak volume of oxygen use of 24 
ml/kg per minute at 3-month follow-up and had 
returned to functional class I. However, he died 
suddenly and autopsy did not reveal the cause of 
death. The second patient had undergone LVAD 
removal for infection and then partial left ventricu- 
lectomy. Seven months later he was admitted to 
another hospital and died rapidly of heart failure. 
One patient with valvular cardiomyopathy under- 
went transplantation 5 months after partial left 
ventriculectomy. This patient died 8 days after trans- 
plantation of right heart failure caused by pulmo- 
nary hypertension resulting from chronic mitral 
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Table II. Intraoperative hemodynamic findings in patients undergoing partial left ventriculectomy 
Preoperative: Postoperative: 
Hemodynamic variable mean (SD) mean (SD) p Value 
Cardiac index (L/min/m z) 
Heart rate (beats/rain) 
Blood pressure systolic (ram Hg) 
Blood pressure mean (ram Hg) 
Blood pressure diastolic (ram Hg) 
Left atrial pressure (mm Hg) 
Pulmonary artery systolic (mm Hg) 
Pulmonary artery mean (ram Hg) 
Pulmonary artery diastolic (mm Hg) 
2.2 (0.7) 2.4 (0.5) 0.25 
92 (17) 102 (16) 0.001 
100 (15) 87 (12) <0.001 
73 (11) 63 (9) <0.001 
59 (14) 52 (8) 0.004 
24 (9) 14 (5) <0.001 
49 (14) 38 (8) <0.001 
36 (11) 30 (6) 0.001 
26 (9) 24 (5) 0.16 
valve disease. Of the discharged patients not under- 
going transplantation, 35% (13 patients) are in 
functional class I, 32% (12 patients) are in func- 
tional class II, and 27% (10 patients) are in func- 
tional class III. 
In summary, among the 53 patients there was one 
(1.9%) operative mortality in a patient who required 
LVAD support. There were four other deaths: one 
late after LVAD insertion, one after transplanta- 
tion, and two of cardiac causes after partial left 
ventriculectomy. Actuarial survival at 11 months was 
87%, and actuarial freedom from relisting for trans- 
plantation was 72%. Of the discharged patients who 
did not undergo transplantation, 67% were in func- 
tional class I or II. Of all 53 patients, 25 (47%) were 
in class I or II after partial left ventriculectomy. 
Most failures occurred early after the operation 
(Fig. 5). 
Discussion 
The concept of reducing LV volume to improve 
function of the remaining LV muscle is not new. LV 
aneurysmectomy reduces LV cavity size to treat 
heart failure. 21-23 The mechanism of action is 
thought to relate to improvement in wall tension 
and myocardial efficiency resulting from effects en- 
gendered by the law of Laplace. Partial left ventric- 
ulectomy differs from aneurysmectomy in that the 
LV scar is not removed; instead, viable but over- 
distended LV muscle is resected. 15' 16 Theoretically, 
this procedure rapidly reverses the detrimental re- 
modeling associated with dilated cardiomyopathy 
and heart failure. Early experience, however, leaves 
many unanswered questions: Who are the best 
candidates? How much muscle can or should be 
removed? What is the role of mitral valve repair in 
the clinical outcome? What are the early hemody- 
namic and physiologic effects? Are the early changes 
temporary or sustained? How does the underlying 
myocardial disease and myocyte function correlate 
with early and late clinical outcomes? What are the 
molecular biodynamic effects of the operation on 
remaining muscle? What is clear from the experi- 
ence in Brazil is that for some patients in NYHA 
class IV the operation returns the patient o class I, 
and this improvement may be sustained for years. 
With this knowledge and the overwhelming need for 
alternatives to cardiac transplantation, we prospec- 
tively studied this operation. Our clinical experi- 
ence, length of follow-up, and analyses do not yet 
allow us to answer these questions. 
We decided to perform partial left ventriculec- 
tomy only in those without extensive myocardial scar 
or fibrosis. We reasoned that constructing a smaller 
heart that remained extensively scarred would pro- 
duce minimal benefit. Attesting to the relative lack 
of specificity of coronary angiography, we found 
unexpected scar in two patients: both required 
LVAD insertion. One other patient failed to im- 
prove and continued to wait status I until transplan- 
tation: pathologic examination of the heart demon- 
strated extensive myocardial fibrosis. Another 
patient had unexpected myocarditis and is awaiting 
transplantation. In future analyses we will compare 
histologic characteristics with clinical outcomes, 
which may permit correlation of preoperative stud- 
ies with myocardial histology and allow us to more 
reliably predict outcome. 
We sought o return the LV end-diastolic dimen- 
sion to near normal. Preoperative echocardio- 
graphic measurements allowed us to predict what 
the diameter of the ventricle would be after resec- 
tion. If papillary muscles had to be resected, the 
posterior wall was usually thinner than the anterior 
wall. We therefore preferentially resected the pos- 
terior papillary muscle and posterior wall. Preoper- 
ative echocardiographic studies typically suggested 
that the lateral LV wall contraction was the most 
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Fig. 5. At 11 months, actuarial survival was 87%, and actuarial freedom from relisting for transplantation 
was 72%. Most failures necessitating relisting for transplantation ccurred early. 
vigorous. After resection, the septum and anterior 
wall showed the best contractility, and the area 
immediately adjacent to the ventriculotomy was 
relatively akinetic. 
By performing the Alfieri mitral valve repair, 
Batista significantly decreased mitral regurgita- 
tion. 16 Bolling 24 and Bach 25 and their colleagues 
have shown that patients with severe ventricular 
dysfunction and severe mitral regurgitation improve 
clinically after mitral valve repair alone. Because the 
mitral regurgitation potentially contributed to the 
symptoms in our patients, and because we wanted to 
avoid progressive LV dilatation caused by volume 
overload from residual mitral regurgitation, we be- 
gan to add posterior annuloplasty for all our pa- 
tients, even if the preoperative mitral regurgitation 
was only 1 to 2+. In addition, our early studies 
confirmed that with normal pliable mitral valve 
leaflets, the Alfieri repair produced very low pres- 
sure gradients and an acceptable mitral valve orifice. 
The contribution of mitral valve repair to overall 
clinical improvement remains to be determined. 
Many of our patients whose condition clinically 
improved after partial left ventriculectomy and mi- 
tral valve replacement had only 2+ mitral regurgi- 
tation before the operation; therefore it is unlikely 
that mitral valve replacement played the primary 
role in the clinical improvement for these patients. 
However, for patients with 4+ mitral regurgitation, 
mitral valve repair may have had a synergistic, or 
even predominant, effect in clinical improvement. 
Our early follow-up indicates that clinical im- 
provement will be sustained for months in most 
patients. In general, the failures have been early 
after the procedure, during the initial hospitaliza- 
tion. After discharge, clinical deterioration so that 
patients were relisted for transplantation was un- 
common (three patients). At this time, however, we 
do not have enough follow-up to predict how long 
these changes will persist. Clinical follow-up from 
Batista indicates that at least some patients will have 
persistent improvement for up to 4 years after the 
operations. 16
From our early experience we draw the following 
initial conclusions. Many patients with idiopathic 
dilated cardiomyopathy and mitral regurgitation will 
show significant clinical benefit from mitral valve 
repair with partial eft ventriculectomy. Failures that 
occur early after the operation may be from myo- 
cardial fibrosis, other myocyte inflammatory pro- 
cesses (myocarditis), and ischemic ardiomyopathy. 
It is our impression that a favorable clinical re- 
sponse to inotropic agents and a dobutamine cho- 
cardiographic study showing improvement in myo- 
cardial contractility may help identify patients who 
will respond well to surgery. However, this ventricu- 
lectomy improves heart function but does not return 
it to normal. Patients with extremely poor LV 
function (e.g., 5% forward LV ejection fraction and 
stroke volume less than 20 ml) may not realize 
enough improvement to live through the perioper- 
ative period and then return to functional class I or 
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II. Until we improve our predictors of outcome, we 
will continue with our strategy to offer ventriculec- 
tomy Primarily to transplant candidates. These early 
conclusions are tentative and can only be verified 
with further clinical experience, longer follow-up, 
and further analyses of prospectively gathered data. 
However, our overall clinical impression is that the 
operation may serve as a relatively inexpensive 
"biologic" bridge to transplantation for some UNOS 
status I patients, and, at best, it may benefit other 
patients for many years and be an alternative to 
transplantation or medical therapy for patients who 
are not candidates fo r transplantation. 
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Discussion 
Dr. D. Craig Miller (Stanford, Calif.). All of us have had 
the pleasure of hearing the second rigorous scientific 
presentation of the clinical results of the Batista proce- 
dure, with the Silo Paulo group presenting the first proper 
report last fall at the meeting of the American Heart 
Association. This is a much better forum than 20/20 or 
Nova or the New York Times or even the National Enquirer 
to assess these results. 
I congratulate Dr. McCarthy and his coworkers for their 
efforts to elucidate whether partial left ventriculectomy 
works, and if so, why it works. I also compliment them for 
their cautious initial approach, which retained fall-back 
safety nets, namely resorting to the use of LVADs and 
transplantation. This work is a fine example of a careful, 
prospective investigation, albeit lacking a suitable control 
group, which brings me to my first and most important 
question. 
Our medical colleagues treating patients who have 
heart failure have achieved astoundingly good results in 
possibly similar patients using angiotensin-converting e - 
zyme inhibitors and beta blockers, if the patient can 
initially be tuned. This "tuning" step is a big caveat. 
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Indeed the use of carvedilol in patients with dilated 
cardiomyopathy now goes by the moniker "medical 
Batista procedure." Dr. McCarthyl were your candidates 
for partial left ventriculectomy judged too sick by Drs. 
Young and Starling for such treatment or had this ap- 
proach already failed? If not, could they have possibly 
been randomized for control purposes? If so, why did you 
not elect to randomize them? On the basis of what you 
have learned so far, do you have any future plans for a 
randomized trial? 
Second, the 87% survival and 72% free-from-transplant 
relisting figures at 1! months are major improvements 
over the Silo Paulo results. In what respect do you 
attribute this to the prophylactic use of amiodarone with 
or without a n automatic implantable cardioverter-defibril- 
lator? 
Third, focusing on technique, I believe you currently 
strive at all costs to avoid reimplanting the anterolateral 
papillary muscle. Could you amplify what problems this 
caused you early on? Also, given the fact that at least four 
patients, 8% of your series, sustained left atrial thrombo- 
sis, what are your thoughts now concerning anticoagula- 
tion? 
Fourth, and perhaps most telling, are you seeing any 
signs of recurrent LV dilatation in patients with 9 months' 
follow-up or more? Partial left ventriculectomy may well 
potentially be a biologic bridge to transplantation, but it 
could turn out to be a very short bridge. 
I will not explain in detail why ejection fraction must 
increase after partial left ventriculectomy as a result of 
simple changes in geometry and ventricular mechanics. 
Simply put, if the laws of physics are the same in the 
Northern Hemisphere as they are in the Southern Hemi- 
sphere, the increase in LV ejection fraction is not myste- 
rious or mythical; it is predictable. 
Dr. Fernando A. Lncehese (Porto Alegre, Brazil). Please 
allow me, as a Brazilian and old friend of Dr. Batista, to 
comment about the creator of this intriguing idea. This 
partial eft Ventriculectomy is just one of the many incred- 
ible ideas he has shared with us, as were stentless aortic 
valves, surgical treatment of atrial fibrillation, and red.uc- 
tion of pulmonary hypertension in Eisenmenger's syn- 
drome. 
1 would like to mention briefly our experience with 42 
cases of Batista's procedure. The main difference with Dr. 
McCarthy's cases is that most of our patients were not 
candidates for transplantation, for a variety of reasons. 
They were already in the hospital, receiving maximum 
medical therapy. Hospital mortality was 16% and 2-year 
actuarial survival was around 40%. Before the operation, 
four survivors had high pulmonary resistance as a contra- 
indication for transplantation, varying from 6 to 8 Wood 
units. From 6 to 12 months after the operation, pulmonary 
resistance dropped to 2 to 3Wood units. One of these 
patients underwent successful transplantation 18 months 
after Batista's procedure. As the first center to do this 
operation after Batista, we think there is a place for it. 
Further studies are obviously needed. 
Dr. Akira T. Kawaguchi (Kanagawa, Japan). It was in 
the AATS meeting 3years ago in Boston that there was a 
discussion on cardiac volume reduction of the left atrium. 
When we reported an increased incidence of atrial fibril- 
lation after the modified maze procedure in patients with 
a larger left atrium, with Dr. Cox as the moderator, Dr. 
Batista showed that simple reduction in left atrial dimen- 
sion ablated atrial fibrillation as well. He went on to apply 
the same mass/radius concept on the LV 3 months later. 
We started coilaborating and studied 70 patients by means 
of pressure-volume loop analysis immediately before and 
after the partial left ventriculectomy. 
In brief, reduction in LV volume improves all the 
indices of systolic function, but it is at the cost of diastolic 
dysfunction, which was not apparent in the previous 
experience with the left atrium because the atrium works 
as a conduit in diastole rather than as a contractile 
chamber. On the average, total energy consumption of the 
LV decreased more than the stroke work, improving 
myocardial energy efficiency. 
This observation, however, does not seem to fully 
account for the improvements we see after ventriculec- 
tomy. We think that our pressure-volume observation was 
made too early after the operation because 20 other 
patients undergoing angiographic study 9 days after the 
same procedure had an increased stroke volume at un- 
changed end-diastolic pressure, indicating improved LV 
function. These observations made us speculate that re- 
duction in mitral regurgitation may be mainly responsible 
for the hemodynamic mprovements immediately after 
partial left ventriculectomy, allowing patients to be 
weaned from bypass and to recuperate. Mechanoener- 
getic changes as observed bY pressure-volume study would 
improve hemodynamics or course of the underlying dis- 
ease sometime later. 
Dr. Gregory A. Misbaeh (San Bernardino, Calif.). The 
authors are tO be congratulated for their careful patient 
selection and careful analysis of results in helping us to 
understand how to apply the Batista procedure. One 
continuing puzzle will be whether in idiopathic dilated 
cardiomyopathy the initiating cause of dilation will recur 
and dilate the hearts once again after the Batista proce- 
dure. It seems that the larger series in this country will 
come out of transplant centers where there are tertiary 
referrals and thousands of patients from whom to select, 
such as in The Cleveland Clinie. I think there is, however, 
one reason for more of us to have some familiarity with 
the Batista technique. Dr. Dor has presented persuasive 
information that argued for the broadening of application 
of endoventricular patch repair to postinfarction LV 
aneurysms, not just to areas that are dyskinetic but also to 
areas that are akinetic. Dr. McCarthy, although patients 
with diffuse fibrosis on magnetic resonance imaging scan 
are poor candidates for partial left ventriculectomy, do 
you believe those with localized fibrosis in one region of 
the heart might be candidates for a modified Batista 
technique where the worst portion of the heart that is 
virtually akinetic is excised, the diameter is reduced, and 
the resultant wall tension reduction combined with coro- 
nary grafting can benefit he residual contractile areas? 
Dr. Nisayoshi Suma (Karnakura, Japan). My question 
concerns the preoperative evaluation of the LV charac- 
teristic itself, not the ventricular function. What kind of 
evaluation before the operation did you do to define the 
ventricular wall characteristic and what did you learn? 
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Dr. McCarthy. I would like to thank all the discussants 
for their points. 
First for Dr. Miller, our control patients were patients 
otherwise going on to transplantation. These 53 patients 
were chosen from among literally thousands of referrals 
that we received after the media blitz. We chose patients 
who were very sick, who my cardiology colleagues thought 
would not respond to beta blockers. Carvedilol is cur- 
rently indicated for patients with class II or III heart 
failure. Experience in patients with class IV heart failure 
is very limited. If you look at the carvedilol trial published 
in the New England Journal of Medicine, the survival in the 
placebo group was quite good, so the population studied 
was not as sick as ours. It is important that 44% of our 
patients were in the hospital receiving inotr0pic drugs, 
and therefore status I, and had had unsuccessful previous 
medical therapy. 
Will this become arandomized trial? First, who is going 
to pay for it? It won't be a drug study or a device study, so 
no company will stand to benefit by paying for the study. 
The National Institutes of Health is not ready to fund a 
study at this point. Second, historically enrollment in 
other surgical randomized trials, such as the REMATCH 
LVAD trial, or cardiomyoplasty, has been slow because of 
very difficult inclusion/exclusion criteria. Third; we think 
that with more experience we may be able to compare our 
results with the real control population, transplant pa- 
tients. We already know those results: 20% die waiting for 
a heart, 15% to 20% die the first year, and 4% to 5% die 
every year after transplantation. Finally, we are still on the 
learning curve regarding selection, technique, and post- 
operative care. If we start a trial too early it may not show 
the potential of this operation. 
We used amiodarone in all of the patients after the 
operation. Amiodarone probably contributes to the low 
risk of sudden death that we have seen so far. Only one 
patient required a new defibrillator, and there has been 
only one sudden cardiac death, which is very different 
from the Brazilian experience. We started amiodarone 
because of what we had learned from the sudden death 
rate in Brazil. 
We try not to resect the anterior papillary muscle 
because the echocardiogram typically shows that the 
anterior wall and the septum do most of the work after the 
resection. Therefore, if possible, we simply resect the 
posterior papillary muscle and leave the anterior papillary 
muscle. 
We have seen a high rate of left atrial thrombus 
formation, and all patients now are placed on a regimen of 
warfarin sodium (Coumadin). Even so, we have Seen left 
atrial thrombus form despite therapeutic levels of warfa- 
rin. I think it reflects the low flow state in some of these 
patients with end-stage heart failure. 
We do not have enough long-term follow-up yet to 
make definitive statements about late recurrence of LV 
dilatation, but we have not seen this yet in the patients 
that we have observed. At 3 months their echocardi0- 
grams look the same as at 1 week. I am certain that 
redilation will occur in some patients, but as yet we have 
not seen that. 
Dr. Misbach, if LV scar can be identified and removed, 
that should improve LV function. Preoperatively, we have 
not been able to consistently identify regional differences 
in scar location in dilated cardiomyopathy. 
We purposely excluded patients with ischemic ardio- 
myopathy from our study. We already know that aneurys- 
mectomy, or patch repair as noted by Dr. Dor, improves 
function in the remaining LV. The contribution of Dr. 
Batista was not regarding that principle for ischemic 
cardiomyopathy; rather it was the new idea to extend that 
concept o dilated cardiomyopathy. 
Dr. Suma, your question addresses what is now our 
most important area of research: correlating the preoper- 
ative studies with the pathologic haracteristics of the 
myocardium and then with clinical outcome. Preoperative 
studies included echocardiograms, tress echocardio- 
grams, positron emission tomographic scans with fluoro- 
deoxyglucose, and magnetic resonance imaging studies. 
This analysis will be difficult and will take time. No easy 
answer has presented itself. However, in our early expe- 
rience we think that a favorable response to dobutamine 
echocardiogram and a positron emission tomogram/flu- 
orodeoxyglucose can showing little fibrosis will predict a 
good outcome. 
